TP53 Gain-of-Function and Non-Gain-of-Function Mutations Are Associated With Differential Prognosis in Advanced Pancreatic Ductal Adenocarcinoma.

Minggui PanChen JiangZheyang ZhangNinah AchacosoStacey AlexeeffAleyda V Solorzano-PintoPam TseElaine ChungTilak SundaresanJennifer Marie SugaSachdev ThomasLaurel A Habel

Published in: JCO precision oncology (2023)

GOF and non-GOF mutp53 were associated with differential prognosis in advanced PDAC. The adverse effect of mutKRAS on OS appeared to be primarily driven by patients with mutCDKN2A. Our results provide new insight that could be helpful for prognostic stratification in clinical practice and for aiding future clinical trial designs.

Keyphrases

clinical trial
clinical practice
emergency department
randomized controlled trial
study protocol
open label
electronic health record